COVID And Beyond: China Urged To Address Chronic Disease, Improve Access
Issues Laid Bare By Coronavirus
Executive Summary
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.
You may also be interested in...
China's New Hong Kong Security Law To Derail Biotech IPOs?
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.